David Morens awaits sentencing after admitting to trying to avoid Freedom of Information Act requests
Researchers who study HIV, tuberculosis, and other infectious disease in the country welcome policy change
Trial failed of supposedly potent antibodies that the leading vaccine candidates aim to trigger
Gilead is criticized for lack of affordable access to lenacapavir in Latin America
One shot of lenacapavir can protect for 6 months—but aid cuts and uncertain demand mean little drug has reached the countries that most need it
Specific class of immune cells help keep virus at bay for months or years—even in the absence of drugs
Specific class of immune cells help keep virus at bay for months or years—even in the absence of drugs
A retreat from investments in drugs and vaccines leaves U.S. less prepared for the next viral scourge, experts warn
A retreat from investments in drugs and vaccines leaves U.S. less prepared for the next viral scourge, experts warn
Culling proceeds after Canada’s Supreme Court ends heated 11-month battle over the fate of more than 300 birds
Culling proceeds after Canada’s Supreme Court ends heated 11-month battle over the fate of more than 300 birds
Science historian Nathaniel Comfort reflects on the “most famous scientist of the 20th century, and the most infamous of the 21st”
Science historian Nathaniel Comfort reflects on the “most famous scientist of the 20th century, and the most infamous of the 21st”
Entering its second decade, philanthropy with Facebook fortune has shed social causes and now focuses on ambitious science dream
Entering its second decade, philanthropy with Facebook fortune has shed social causes and now focuses on ambitious science dream